ORIGINAL RESEARCH ARTICLES

Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection
Dellay B., et al.

Conversion from Vancomycin Trough Concentration–Guided Dosing to Area Under the Curve–Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center
Meng L., et al.

Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study
Hart E., et al.

Assessment of Ketamine Adult Anesthetic Doses in Pediatrics Using Pharmacokinetic Modeling and Simulations
Elkomy M.H., et al.

REVIEWS OF THERAPEUTICS

Glucagon for Relief of Acute Esophageal Foreign Bodies and Food Impactions: A Systematic Review and Meta-Analysis

Tolvaptan for Volume Management in Heart Failure
Gunderson E.G., et al.

Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States
Adams J.L., et al.

BRIEF REPORTS

Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus
Navarro J., et al.

Synthetic Cannabinoid-Associated Multiple Organ Failure: Case Series and Literature Review
Armstrong F., et al.

Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study
Lê M.P., et al.

CASE REPORT

Use of Cangrelor as a Bridge to Left Ventricular Assist Device Implantation in a Patient with a Recent Drug-Eluting Stent Who Developed Acute Tirofiban-Related Thrombocytopenia
PHARMACOTHERAPY

SCOPE AND PURPOSE

Pharmacotherapy is devoted to publication of original research articles on all aspects of human pharmacology/pharmacotherapy and review articles on drugs and drug therapy. The Editors and Editorial Board invite original research reports and review articles on pharmacokinetics and pharmacogenomics properties of drugs, personalized medicine, drug interactions, clinical trials and new drug development, investigations of specific pharmacological properties of drugs, and related topics.

Original reports are published in one of the following departments:

- **Original Research Articles.** These are full-length original research articles, representing substantial, novel research in areas such as therapeutics, pharmacokinetics, pharmacodynamics, pharmacogenomics, and pharmacoeconomics. Word and reference limits: Text: 3,500 words, excluding abstract, references, tables, and figures; Structured Abstract: 300 words; References: 50 maximum.
- **Brief Reports.** These are either preliminary original research reports or studies that have a high potential for significant clinical impact or hybrid reports embracing a small case series with a clear research question posed and answered. Word and reference limits: Text: 2,000 words, excluding abstract, references, tables, and figures; Structured Abstract: 250 words; References: 30 maximum.
- **Case Reports.** Pharmacotherapy only accepts case reports that represent truly novel and substantial findings of unambiguous causality; they must expand the clinician’s understanding of contemporary drug therapy and represent significant contributions to the literature. All case reports that detail a purported drug-induced effect or a drug effect are required to use and report the results of an objective assessment algorithm, such as the Naranjo algorithm (see Naranjo CA, Busto U, Sellers EM, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239–45).
- **Letters to the Editor.** This correspondence clarifies or challenges any of our previously published articles and, whose publication, would benefit the readership in general. Submissions to this department must be received within 3 months of the publication of the article in question and are limited to a maximum of 300 words.

All manuscripts are subject to review by qualified consultants and the editors, and are accepted for publication if they are thought to be important contributions to the biomedical literature. Authors are invited to contact the editor to clarify any issues. The manuscript requirements of Pharmacotherapy generally conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (Ann Intern Med 1986;95:1-15).

The content of Pharmacotherapy is protected by copyright. Manuscripts are accepted for publication with the understanding that their contents, all or in part, have not been published elsewhere, except in abstract form, or by the express consent of the editor. Pharmacotherapy accepts no responsibility for statements made by contributors.

Secondary services that cover articles in Pharmacotherapy include Biological Abstracts, Chemical Abstracts, Current Contents, Excerpta Medica, Index Medicus, Current Awareness in Biological Sciences, and Referativnyi Zhurnal. Pharmacotherapy is microfilmed by University Microfilms International of Ann Arbor, Michigan.


PUBLICATION CHARGES

All papers published in Pharmacotherapy will be subject to a $100.00 publication fee, to be assessed at the time papers are accepted for publication.